Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunesis Reduces Workforce to Focus on Development of PDK1 inhibitor, SNS-510","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sunesis Announces Pricing of $12 Million Offering of Common Stock","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sunesis Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Viracta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Sunesis Pharmaceuticals","sponsor":"Viracta Therapeutics","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Sunesis Pharmaceuticals

    Menu

    Sunesis Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Sunesis Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement

              Details:

              Viracta's lead program (VRx-3996) evaluates the all-oral combination of nanatinostat, its proprietary investigational drug, and valganciclovir in a Phase 2 clinical trial for the treatment of EBV-positive relapsed/refractory (R/R) lymphoma.

              Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride

              Therapeutic Area: Oncology Product Name: VRx-3996

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: Viracta Therapeutics

              Deal Size: $120.0 million Upfront Cash: Undisclosed

              Deal Type: Merger February 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sunesis Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

              Details:

              The merger will focus on the advancement and expansion of Viracta’s clinical stage, precision oncology pipeline including Viracta’s lead program of all-oral combination of nanatinostat and valganciclovir to teat Epstein-Barr virus-positive relapsed/refractory lymphomas.

              Lead Product(s): Nanatinostat,Valganciclovir Hydrochloride

              Therapeutic Area: Oncology Product Name: VRx-3996

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: Viracta Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger November 30, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sunesis Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sunesis Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

              Details:

              Abstract titled "PDK1 inhibitor SNS-510 shows synergy with standard cancer therapies in solid tumor and hematologic cancer models " will be presented at the conference.

              Lead Product(s): SNS-510

              Therapeutic Area: Oncology Product Name: SNS-510

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 12, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sunesis Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sunesis Announces Pricing of $12 Million Offering of Common Stock

              Details:

              Sunesis anticipates using the net proceeds from the proposed offering to fund ongoing development of PDK1 inhibitor SNS-510 and general corporate purposes.

              Lead Product(s): SNS-510

              Therapeutic Area: Oncology Product Name: SNS-510

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Oppenheimer & Co. Inc.

              Deal Size: $12.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering July 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sunesis Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sunesis Reduces Workforce to Focus on Development of PDK1 inhibitor, SNS-510

              Details:

              The changes will extend Sunesis's cash runway and provide it with the necessary resources to execute on its PDK1 program evaluating its PDK1 inhibitor SNS-510, while also allowing the flexibility to explore opportunities for additional value creation.

              Lead Product(s): SNS-510

              Therapeutic Area: Oncology Product Name: SNS-510

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Sunesis Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program

              Details:

              Company will not advance its non-covalent BTK inhibitor vecabrutinib into the planned Phase 2 portion of the Phase 1b/2 trial in adults with relapsed/refractory chronic lymphocytic leukemia and other B-cell malignancies.

              Lead Product(s): Vecabrutinib

              Therapeutic Area: Oncology Product Name: SNS-062

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY